



# NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support 11 Apr 2022 (#14)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit [www.grants.nih.gov](http://www.grants.nih.gov) or [www.sun.ac.za/RDSfunding](http://www.sun.ac.za/RDSfunding) (current & archive).

**Confirm your intent to apply ASAP, but not later than 60 days before the submission date.**

Tygerberg Campus: [cdevries@sun.ac.za](mailto:cdevries@sun.ac.za) • Stellenbosch Campus [lizelk@sun.ac.za](mailto:lizelk@sun.ac.za)

## Important Notices

- **Urgent: Financial Conflict of Interest: All Principal Investigators (PIs) and Key Personnel (KP) of all current NIH grants, direct and subawards, must complete the NIH training and submit the certificate the Grants Management Office)** For all new applications, all PI's & KP must complete the certificate before the application can be submitted to NIH. This is in addition to the FCOI declarations that must be signed.
  - FMHS contact: [cdevries@sun.ac.za](mailto:cdevries@sun.ac.za)
  - Stellenbosch Campus contact [lizelk@sun.ac.za](mailto:lizelk@sun.ac.za).

Link to the training: [https://grants.nih.gov/grants/policy/coi/tutorial2018/story\\_html5.html](https://grants.nih.gov/grants/policy/coi/tutorial2018/story_html5.html)

## Parent Announcements

Parent Announcements (PA) for unsolicited are broad funding opportunity announcements allowing applicants to submit investigator-initiated applications. They are open for up to 3 years and use standard due dates.

- [PA-20-185](#) NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- [PA-20-184](#) Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
- [PA-20-183](#) Research Project Grant (Parent R01 Clinical Trial Required)
- [PA-20-200](#) NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
- [PA-20-195](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
- [PA-20-194](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
- [PA-20-196](#) NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

## Funding Opportunity Announcements (FOA)

### 1. Development and Optimization of Next-Generation Immunological Assays to Support Influenza Clinical Studies and Trials (UH2/UH3 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [RFA-AI-22-020](#)

Type: UH2/UH3

Application Due Date: 1 July 01, 2022. Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications for collaborative, multidisciplinary research to develop and optimize next-generation immunological assays that will be readily utilized for influenza clinical studies and trials by the end of the UH2/UH3 project period.

**Budget:** NIAID intends to commit \$5 million in FY 2023 to fund 3-5 awards. For the UH2 phase, the direct cost is limited to \$500,000 per year. For the UH3 phase, the direct cost is limited to \$500,000 per year. The proposed project period for the initial phase (UH2) must not exceed 2 years. The proposed project period for the subsequent phase (UH3) must not exceed 3 years.

**2. Partnerships for the Development of Novel Therapeutics to Combat Select Antibiotic Resistant Bacteria and Fungi (R01 Clinical Trial Not Allowed)**

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [RFA-AI-22-028](#)

**Type:** R01

**Application Due Date:** 29 July 2022. Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** The purpose of this Funding Opportunity Announcement (FOA) is to solicit research applications for milestone-driven projects focused on preclinical development of lead candidate therapeutics and related countermeasures against antibiotic resistant *Acinetobacter baumannii*, *Pseudomonas aeruginosa*, *Enterobacteriaceae*, or *Candida auris*. Applications must include a Product Development Strategy attachment. Substantive investment by industrial participants is highly encouraged.

**Budget:** NIAID intends to commit \$4M in FY 2024 to fund 6-8 awards. Recommended budget for direct costs of up to \$650,000 per year may be requested. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

**3. Transformative Research Award for the INCLUDE (Investigation of Co-occurring Conditions across the Lifespan to Understand Down syndrome) Project (R01 Clinical Trial Not Allowed)**

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [RFA-OD-22-009](#)

**Type:** R01

**Application Due Date:** 1 July 2022; 2023; 2024. Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** The NIH Investigation of Co-occurring conditions across the Lifespan to Understand Down syndrome (INCLUDE) Project seeks to improve health and quality-of-life for individuals with Down syndrome. This Funding Opportunity Announcement (FOA) is soliciting Transformative Research Award applications to support individual scientists or groups of scientists proposing groundbreaking, exceptionally innovative, original, and/or unconventional research that has the potential to create new scientific paradigms, establish entirely new and improved clinical approaches, or develop transformative technologies related to Down syndrome. For the program to support the best possible researchers and research, applications are sought which reflect the full diversity of the nation's research workforce. Individuals from diverse backgrounds, including those from underrepresented groups and from the full spectrum of eligible institutions in all geographic locations are strongly encouraged to apply to this Funding Opportunity Announcement. Applications are welcome in all topics relevant to Down syndrome-related research or its co-occurring conditions. No preliminary data are required. Projects must clearly demonstrate, based on the strength of the logic, a compelling potential to produce a major impact in research related to Down syndrome.

**Budget:** The NIH intends to commit total costs of at least \$6,000,000 in FY2022 to fund up to four awards. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is five years.

**4. Research Projects in Physical Sciences-Oncology (U01 Clinical Trial Optional)**

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [PAR-22-147](#)

**Type:** U01

**Application Due Date:** 8 July 2022 through to 1 November 2024. Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** This Funding Opportunity Announcement (FOA) invites U01 cooperative agreement applications for Physical Science-Oncology Projects (PS-OP). The goal of the Physical Sciences-Oncology Network (PS-ON) is to foster the convergence of physical sciences approaches and perspectives with cancer research to advance our understanding of cancer biology and oncology by forming transdisciplinary teams of physical scientists and cancer biologists/physician scientists. Examples of physical scientists may include engineers, physicists, mathematicians, chemists, and computer scientists. The PS-OPs, individually and as a collaborative Network along with other PS-OPs and the Physical Sciences-Oncology Centers (PS-OC), will support transdisciplinary research that: (1) establishes a physical sciences perspective within the cancer research community; (2) facilitates team science and field convergence at the intersection of physical sciences and cancer research; and (3) collectively tests physical sciences-based experimental and theoretical concepts of cancer and promotes innovative solutions to address outstanding questions in cancer research.

**Budget:** Direct costs requested may not exceed \$400,000 per year. The budget must reflect the actual needs of the proposed project. Project periods of up to 5 years may be proposed.

**5. Laboratories to Optimize Digital Health (R01 Clinical Trial Required)**

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [PAR-22-154](#)

**Type:** R01

**Application Due Date:** 5 June 2022 through to 5 February 2025. Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** National Institute of Mental Health (NIMH) seeks applications for innovative research projects to test strategies to increase the reach, efficiency, effectiveness, and quality of digital mental health interventions which may impact mental health outcomes, including suicide behaviors and serious mental illness. This Funding Opportunity Announcement (FOA) is intended to support the development of digital health test beds that leverage well-established digital mental health platforms and infrastructure to rapidly refine and optimize existing evidence-based digital health interventions and to conduct clinical research testing digital mental health interventions that are statistically powered to provide a definitive answer regarding the intervention's effectiveness particularly in populations who experience health disparities and vulnerable populations.

**Budget:** Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 4 years.

#### 6. Alcohol Health Services Research (R01 Clinical Trial Optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [PAR-22-156](#)

**Type:** R01

**Application Due Date:** 5 June 2022; 5 October 2022; 5 Feb 2023. Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** The National Institute on Alcohol Abuse and Alcoholism solicits applications for an R01 Clinical Trial Optional mechanism focusing on alcohol health services. This FOA will broadly focus on closing the treatment gap for individuals with alcohol use disorder (AUD); within this focus, there are five major areas of emphasis: (1) increasing access to treatment for AUD, (2) making treatment for AUD more appealing, (3) examining cost structures and insurance systems, (4) conducting studies on dissemination and implementation of existing evidence-based approaches to treating AUD, and (5) reducing health disparities as a means of addressing the treatment gap in AUD for health disparity populations.

**Budget:** Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years. Applicants requesting \$500,000 or more in direct costs in any year (excluding consortium F&A) must contact a Scientific/ Research Contact at least 6 weeks before submitting the application.

#### 7. Alcohol Health Services Research (R34 Clinical Trial Optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [PAR-22-157](#)

**Type:** R34

**Application Due Date:** 16 June 2022; 16 October 2022; 16 February 2023. Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** The National Institute on Alcohol Abuse and Alcoholism solicits applications for an R34 Clinical Trial Optional mechanism focusing on alcohol health services. This FOA will broadly focus on closing the treatment gap for individuals with alcohol use disorder (AUD); within this focus, there are five major areas of emphasis: (1) increasing access to treatment for AUD, (2) making treatment for AUD more appealing, (3) examining cost structures and insurance systems, (4) conducting studies on dissemination and implementation of existing evidence-based approaches to treating AUD, and (5) reducing health disparities as a means of addressing the treatment gap in AUD for health disparity populations.

**Budget:** Direct costs are limited to \$450,000 over the R34 project period, with no more than \$225,000 in direct costs allowed in any single year. The total project period for an application submitted in response to this FOA may not exceed 3 years.

#### 8. Alcohol Treatment and Recovery Research (R01 Clinical Trial Required)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [PAR-22-158](#)

**Type:** R01

**Application Due Date:** 5 June 2022; 5 October 2022; 5 February 2023. Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** The National Institute on Alcohol Abuse and Alcoholism solicits applications for an R01 Clinical Trial Required mechanism focusing on alcohol treatment and recovery research. This FOA will focus broadly on topics relevant for treatment of and recovery from alcohol use disorder (AUD), including: medications development, precision medicine, behavioral therapies and mechanisms of behavioral change (MOBC), recovery, translational research, and innovative methods and technologies for AUD treatment and recovery.

**Budget:** Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years.

#### 9. Alcohol Treatment and Recovery Research (R34 Clinical Trial Required)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [PAR-22-159](#)

**Type:** R34

**Application Due Date:** 16 June 2022; 16 October 2022; 16 February 2023. Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** The National Institute on Alcohol Abuse and Alcoholism solicits applications for an R34 Clinical Trial Required mechanism focusing on alcohol treatment and recovery research. This FOA will focus broadly on topics relevant for treatment of and recovery from alcohol use disorder (AUD), including: medications development, precision medicine, behavioral therapies and mechanisms of behavioral change (MOBC), recovery, translational research, and innovative methods and technologies for AUD treatment and recovery.

**Budget:** Direct costs are limited to \$450,000 over the R34 project period, with no more than \$225,000 in direct costs allowed in any single year. The total project period for an application submitted in response to this FOA may not exceed 3 years.

#### 10. Cancer Epidemiology Cohorts: Building the Next Generation of Research Cohorts (U01 Clinical Trial Not Allowed)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [PAR-22-161](#)

**Type:** U01

**Application Due Date:** 29 July 2022 through 28 February 2025. Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** Through this funding opportunity announcement, the National Cancer Institute (NCI) solicits applications to "Cancer Epidemiology Cohorts: Building the Next Generation of Research Cohorts" PAR. This funding opportunity announcement seeks to support initiating and building the next generation of population-based cancer epidemiology cohorts to address specific knowledge gaps in cancer etiology and survivorship. Specifically, it will support methodological work necessary to initiate and build cancer epidemiology cohorts that can address critical scientific gaps concerning (i) new or unique exposures in relation to cancer risks and outcomes and (ii) achievement of diverse populations in cohorts with the inclusion of understudied populations (e.g., racial/ethnic groups, rural populations, individuals living in persistent poverty areas, and others) with substantial community engagement.

**Budget:** Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years. Applicants requesting \$500,000 or more in direct costs in any year (excluding consortium F&A) must contact a Scientific/ Research Contact at least 8 weeks before submitting the application

### 11. Pediatric Immunotherapy Network (PIN) (U01 Clinical Trial Optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [RFA-CA-22-016](#)

**Type:** U01

**Application Due Date:** 27 September 2022. Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) intends to solicit applications for the Pediatric Immunotherapy Network (PIN). The overall goal of this FOA is to establish a collaborative network consisting of investigators with relevant expertise to develop and advance novel translational immunotherapy approaches for children and adolescents with solid tumors including brain tumors. This FOA solicits U01 applications for discrete research projects that address relevant research opportunities focused on pediatric solid tumors (e.g., mechanisms of immune evasion, development of pre-clinical models, discovery and validation of novel therapeutic targets, development of novel pediatric immunotherapy agents and treatment approaches such as cancer vaccines, cellular therapy, and combinations with immunotherapy agents. Successful applicants will become members of the Pediatric Immunotherapy Network (PIN), which will address current challenges in pediatric cancer immunotherapy and accelerate the pace at which effective immunotherapies are realized for pediatric solid tumors.

**Budget:** NCI intends to commit \$6,000,000 in FY 2023 to fund 6-8 awards. Application budgets may not exceed \$450,000 in direct costs (excluding sub-award F&A costs) per year and must reflect the actual needs of the proposed project. The maximum project period is 5 years.

### 12. Cancer Prevention, Detection, Diagnosis, and Treatment Technologies for Global Health (U01 Clinical Trial Optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [RFA-CA-22-020](#)

**Type:** U01

**Application Due Date:** 17 June 2022. Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** This Funding Opportunity Announcement (FOA) supports the development of cancer-relevant technologies suitable for use in low- and middle-income countries (LMICs). Specifically, the FOA solicits applications for projects to adapt, apply, and validate existing or emerging technologies into a new generation of user-friendly, low-cost technologies for preventing, detecting, diagnosing, and/or treating cancers in people living in LMICs. Applicants should have a working assay or device prototype (not necessarily already capable of cancer applications). The U01 project includes studies to both adapt this technology as well as demonstrate technical functionality and clinical performance for use of the device or assay in specific LMIC settings by meeting objective performance milestones followed by improvements and validations of the technologies in the LMIC settings. Projects proposed in response to this FOA will require multidisciplinary efforts to succeed; therefore, all applicant teams must include expertise in engineering/assay/treatment development, oncology, global healthcare delivery, and business development. Investigators responding to this FOA must consider affordability and cost-effectiveness as well as usability at the point-of-need as part of their design criteria. This funding opportunity is part of a broader NCI-sponsored Affordable Cancer Technologies (ACTs) Program.

**Budget:** NCI intends to commit \$4.0 million to support up to six awards in FY2023. Applicants may request up to \$475,000 in direct costs per year. The proposed project period must not exceed 5 years.

### 13. A Community Research Resource: Characterization of the Resident Ocular Microbiome. (U24 Clinical Trial Not Allowed)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [RFA-EY-22-001](#)

**Type:** U24

**Application Due Date:** 06 July 2022. Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** The overall purpose of this funding opportunity announcement (FOA) is to invite applicants from multidisciplinary research teams to develop a community-based resource of microbial data associated with the resident ocular microbiome of healthy individuals. The data include factors microbial communities elaborate that impact human physiology. This announcement will support research projects designed to: delineate and characterize core ocular microbial constituents in the front of the eye; understand their immune and neuro interactions and contributions to the maintenance of homeostasis; and integrate microbiome, omics, and clinical data to determine profiles that promote health of the ocular surface. The front of the eye or anterior segment includes the ocular surface, cornea, iris, ciliary body, conjunctiva, lens, eyelids, and periocular skin.

**Budget:** The NEI intends to commit up to \$5 million in total costs in FY 2023 to fund up to 6-8 awards. Application budgets are not limited but need to reflect the actual needs of the proposed project. Costs for data sharing and travel expenses to attend in-person annual meetings must be included in the budget request. The scope of the proposed project should determine the project period. The maximum project period is 3 years

### 14. Small Research Grants for Analysis, Curation, and/or Sharing of Down syndrome-related Research Data for the INCLUDE Project (R03 Clinical Trial Not Allowed)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [RFA-OD-22-008](#)

**Type:** R03

**Application Due Date:** 1 July 2022; June 30, 2023; July 01, 2024. Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** The NIH Investigation of Co-occurring conditions across the Lifespan to Understand Down syndrome (INCLUDE) Project seeks to improve health and quality-of-life for individuals with Down syndrome. This FOA is intended to support meritorious small research projects focused on analyses of genomics other -omics, clinical and phenotypic datasets related to Down syndrome research, with an emphasis on elucidating the underlying etiologies of risk and resiliencies to co-occurring health conditions. Development of approaches, tools, or algorithms appropriate for analyzing data relevant to Down syndrome and facilitating data sharing within the research community through the INCLUDE Data Hub may also be proposed.

**Budget:** NIH intends to commit total costs of at least \$600,000 in fiscal year 2020 to fund a minimum of 3 awards. The final number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Future year amounts will depend on annual appropriations. Applications may request budgets of up to \$100,000 in direct costs per year for up to two years. The total project period may not exceed two years.

**15. Clinical Trials Development for Co-Occurring Conditions in Individuals with Down syndrome: Phased Awards for INCLUDE (R61/R33 Clinical Trial Required)**

**Letter of Intent: 30 days prior to the application due date**

**Hyperlink: [RFA-OD-22-010](#)**

**Type: R61/R33**

**Application Due Date:** 1 July 2022; 30 June 2023; 1 July 2024. Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** The NIH INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE (INCLUDE) Project seeks to improve health and quality-of-life for individuals with Down syndrome. This Funding Opportunity Announcement (FOA) encourages Exploratory/Developmental Phased Innovation (R61/R33) grant applications to support development of clinical trials to treat critical and co-occurring health conditions in individuals with Down syndrome. The proposed research aims should be milestone-driven. The total project period for an application submitted in response to this FOA may not exceed five years. This FOA provides support for up to two years (R61 phase) for preliminary/developmental/planning studies, followed by possible transition to clinical trial support (R33) of up to three years, although the total duration of the award may not exceed five years. This FOA requires measurable R61 milestones.

**Budget:** The NIH intends to commit total costs of at least \$4,000,000 in FY2022 to fund up to 4 awards. Application budgets for the R61 phase and the R33 phase are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum period of the combined R61 and R33 phases is 5 years, with up to 2 years for the R61 phase and up to 3 years for the R33 phase.

Research Development and Support Division (RDSD),  
Faculty of Medicine and Health Sciences  
5<sup>th</sup> Floor, Teaching Block, Tygerberg Campus.  
Enquiries: *Christa*  
e: [cdevries@sun.ac.za](mailto:cdevries@sun.ac.za) | t: +27 21 938 9838

Division for Research Development (DRD)  
Stellenbosch Campus  
2041 Krotoa Building, Ryneveld Street  
Enquiries: *Lizél*  
e: [lizelk@sun.ac.za](mailto:lizelk@sun.ac.za) | t: +27 21 808 2105